## HCA: HCA Healthcare, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.3% below STRENGTH zone (3.0-6.0%); PEG 1.27 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($450.59)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Investors Continue Waiting On Sidelines For HCA Healthcare, Inc. (NYSE:HCA)**
- Source: Simply Wall Street | 20260102T102407 | Neutral | Relevance: 100%
- HCA Healthcare (NYSE:HCA) currently has a lower P/E ratio of 16.8x compared to the broader US market, despite recent strong earnings growth. Analysts forecast an 11% annual growth for HCA, mirroring the market average, making its low P/E ratio "peculiar." This suggests investors may be cautious about future earnings volatility or potential unobserved threats, despite the positive outlook.

**2. Investors Continue Waiting On Sidelines For HCA Healthcare, Inc. (NYSE:HCA)**
- Source: Simply Wall Street | 20260102T100752 | Somewhat-Bullish | Relevance: 100%
- HCA Healthcare, Inc. currently has a P/E ratio of 16.8x, which is lower than the broader US market, despite recent strong earnings growth and analyst forecasts for future growth in line with the market. Investors may be skeptical of future earnings stability, leading to the subdued P/E ratio. The article suggests that while the risk of a price drop seems low, investors anticipate some volatility in future earnings.

**3. HCA Healthcare, Inc. $HCA Shares Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al**
- Source: MarketBeat | 20251231T115447 | Somewhat-Bullish | Relevance: 100%
- VIRGINIA RETIREMENT SYSTEMS ET Al increased its stake in HCA Healthcare, Inc. (NYSE:HCA) by 4.2% during the third quarter, making it their 15th largest holding. Several other institutional investors also modified their positions. The article also notes recent insider selling by an HCA executive and provides analyst ratings and financial performance details for the company, including a recent dividend declaration.

**4. Is HCA Healthcare Stock the Next Sleeper Mega-Win or a Disaster Waiting to Happen?**
- Source: AD HOC NEWS | 20260103T052601 | Bullish | Relevance: 100%
- HCA Healthcare (HCA) is presented as a quietly performing stock, contrary to trending meme stocks, due to its strong financial performance, significant market cap, and consistent dividend payouts. The article examines HCA's business model, highlighting its scale, the essential nature of healthcare services, and the risks involved like labor costs and regulatory scrutiny. It concludes that HCA Healthcare, while not a viral sensation, offers long-term stability and growth potential for serious investors.

**5. Marion County HCA Hospitals Now Offering Advanced Robotics for Orthopedic Surgeries**
- Source: 352today | 20260102T182158 | Bullish | Relevance: 100%
- HCA Florida Ocala Hospital and HCA Florida West Marion Hospital are now utilizing advanced robotic systems for total knee, partial knee, and total hip replacement surgeries. This innovative technology allows for personalized surgical planning, increased precision, and better outcomes such as less pain and quicker recovery times for patients. The system combines 3D CT-based planning with haptic technology, enabling surgeons to operate with enhanced accuracy and customize procedures to each patient's unique anatomy.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Mizuho | $520 | $505 | +3% |
| 2025-12-15 | Morgan Stanley | $425 | $425 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Mizuho | main | Outperform |
| 2025-12-15 | Morgan Stanley | down | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($3.12M) |
| Sells | 4 ($14.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 29.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 6.5% (-3.8%)
- Blackrock Inc.: 5.5% (-3.7%)
- Sanders Capital, LLC: 4.7% (-3.9%)
- State Street Corpora: 3.3% (-5.9%)
- JPMORGAN CHASE & CO: 2.6% (+82.2%)

### Key Risks

1. Heavy insider selling: $15M sold (4 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +1.1% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.27 suggests fair value with growth premium. Forward P/E 15.8x stretched relative to 7% growth. Quality metrics strong (ROE 136%, ROA 12%). Balance sheet: $3.1B free cash flow. Insider selling cluster ($14.8M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $110.1B |
| Beta | 1.37 |
| 52W Range | $295.00 - $520.00 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.27 |
| Forward P/E | 15.8 |
| Current P/E | 17.0 |
| YoY Growth | 7.3% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -0.8% to 0.3% (+1.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.7pp (needs >3.0% for momentum thesis). MRS_5 at 0.3% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.17x) but short-term weakness (below SMA20). MACD histogram bearish (-1.37), momentum weakening. RSI neutral at 46. OFD pattern: +MLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.28% (CS: 41) | Neutral |
| RSI_14 | 45.8 | Neutral |
| MACD Histogram | -1.37 | Bearish |
| vs SMA20 | 0.988x | Below |
| vs SMA50 | 0.988x | Below |
| vs SMA200 | 1.171x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $470.39
- **Stop Loss:** $450.59 (4.2% risk)
- **Target:** $490.19 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 72
- **Position Value:** $33,868.08
- **Portfolio %:** 33.87%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-01-23 (Est: $7.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.73 | $6.96 | +21.6% |
| 2025Q2 | $6.32 | $6.84 | +8.2% |
| 2025Q1 | $5.75 | $6.45 | +12.1% |
| 2024Q4 | $6.14 | $6.22 | +1.2% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*